Please login to the form below

Not currently logged in
Email:
Password:

Cornerstone Therapeutics

This page shows the latest Cornerstone Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Chiesi hits the acquisition trail again

Chiesi hits the acquisition trail again

company Cornerstone Therapeutics. ... The value of the deal is around $107m and all in all values Cornerstone at some $255m.

Latest news

  • Biologics buoyant

    Three of the deals, with Amplimmune, FivePrime Therapeutics and Genmab, focus on biologics. ... 84+. Cornerstone Therapeutics/Targacept . Alpha-7 and other nicotinic receptor targeting compounds. Preclinical .

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch table for September 2013 Deal Watch table for September 2013

    Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... Cornerstone Therapeutics, respectively.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...